关注
Alan K. Davis
标题
引用次数
引用次数
年份
Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial
AK Davis, FS Barrett, DG May, MP Cosimano, ND Sepeda, MW Johnson, ...
JAMA psychiatry 78 (5), 481-489, 2021
6452021
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety
AK Davis, FS Barrett, RR Griffiths
Journal of contextual behavioral science 15, 39-45, 2020
2012020
Survey of subjective" God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca …
RR Griffiths, ES Hurwitz, AK Davis, MW Johnson, R Jesse
PloS one 14 (4), e0214377, 2019
1672019
Cessation and reduction in alcohol consumption and misuse after psychedelic use
A Garcia-Romeu, AK Davis, F Erowid, E Erowid, RR Griffiths, ...
Journal of Psychopharmacology 33 (9), 1088-1101, 2019
1642019
Long-term effects of psychedelic drugs: A systematic review
JS Aday, CM Mitzkovitz, EK Bloesch, CC Davoli, AK Davis
Neuroscience & Biobehavioral Reviews 113, 179-189, 2020
1302020
A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy
JB Luoma, C Chwyl, GJ Bathje, AK Davis, R Lancelotta
Journal of Psychoactive Drugs 52 (4), 289-299, 2020
1222020
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
N Gukasyan, AK Davis, FS Barrett, MP Cosimano, ND Sepeda, ...
Journal of Psychopharmacology 36 (2), 151-158, 2022
1082022
The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption
AK Davis, JP Barsuglia, R Lancelotta, RM Grant, E Renn
Journal of Psychopharmacology 32 (7), 779-792, 2018
1042018
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety
AK Davis, S So, R Lancelotta, JP Barsuglia, RR Griffiths
The American journal of drug and alcohol abuse 45 (2), 161-169, 2019
1032019
Acceptance of non-abstinence goals by addiction professionals in the United States.
AK Davis, H Rosenberg
Psychology of Addictive Behaviors 27 (4), 1102, 2013
1022013
Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects
AK Davis, JM Clifton, EG Weaver, ES Hurwitz, MW Johnson, RR Griffiths
Journal of Psychopharmacology 34 (9), 1008-1020, 2020
932020
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder
MK Doss, M Považan, MD Rosenberg, ND Sepeda, AK Davis, PH Finan, ...
Translational psychiatry 11 (1), 574, 2021
892021
Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey
A Garcia-Romeu, AK Davis, E Erowid, RR Griffiths, MW Johnson
Frontiers in Psychiatry, 955, 2020
842020
Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects
JS Aday, AK Davis, CM Mitzkovitz, EK Bloesch, CC Davoli
ACS Pharmacology & Translational Science 4 (2), 424-435, 2021
762021
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences
MT Williams, AK Davis, Y Xin, ND Sepeda, PC Grigas, S Sinnott, ...
Drugs: Education, Prevention and Policy 28 (3), 215-226, 2021
642021
Prospective examination of synthetic 5-methoxy-N, N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
MV Uthaug, R Lancelotta, A Szabo, AK Davis, J Riba, JG Ramaekers
Psychopharmacology 237, 773-785, 2020
612020
Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study
J Barsuglia, AK Davis, R Palmer, R Lancelotta, AM Windham-Herman, ...
Frontiers in psychology 9, 2459, 2018
532018
Self-medication of somatic and psychiatric conditions using botanical marijuana
LA Osborn, KJ Lauritsen, N Cross, AK Davis, H Rosenberg, F Bonadio, ...
Journal of psychoactive drugs 47 (5), 345-350, 2015
522015
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
AK Davis, FS Barrett, S So, N Gukasyan, TC Swift, RR Griffiths
Journal of Psychopharmacology 35 (4), 437-446, 2021
492021
Differences in the acceptability of non-abstinence goals by type of drug among American substance abuse clinicians
H Rosenberg, AK Davis
Journal of Substance Abuse Treatment 46 (2), 214-218, 2014
452014
系统目前无法执行此操作,请稍后再试。
文章 1–20